chufangao/CTO huggingface dataset:
Clinical trial NCT05832255: An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
Official title: An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients
Sponsor: Nova Mentis Life Science Corp (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Indefinite hold due to protocol revisions relating to the exclusion criteria for concurrent medications.
Enrollment: 10.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2023-03-28
Primary completion date: 2024-05-31
Completion date: 2024-05-31
Clinical trial NCT02277223: Curcumin in Pediatric Ulcerative Colitis
Official title: Curcumin for Induction and Maintenance Therapy in Pediatric Ulcerative Colitis
Sponsor: Schneider Children's Medical Center, Israel (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Difficulty to enroll patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-01
Primary completion date: 2022-07-31
Completion date: 2022-12-31
Clinical trial NCT04340232: Safety and Efficacy of Baricitinib for COVID-19
Official title: Safety and Efficacy of Baricitinib for COVID-19
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Could not make FDA required changes
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-31
Primary completion date: 2021-08-31
Completion date: 2021-10-31
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data will be made available for all primary outcome measures.
IPD time frame: Data will be made available upon publication in a peer-reviewed journal.
IPD access criteria: Data access requests will be reviewed by the sponsor-investigator and collaborators.
Clinical trial NCT03688230: Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.
Official title: AMELION: A Randomized, Double Blinded, Phase 2, Efficacy and Safety Study of Abituzumab (EMD 525797) in Combination With Cetuximab and FOLFIRI Versus Placebo in Combination With Cetuximab and FOLFIRI in First-line RAS Wild-type, Left-sided, Metastatic Colorectal Cancer Patients With High ανβ6 Integrin Expression.
Acronym: AMELION
Sponsor: SFJ Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Co-development decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-30
Primary completion date: 2020-12-31
Completion date: 2021-08-31
Clinical trial NCT04488575: Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
Official title: A Phase 2 Double-blind Placebo-controlled Study Investigating the Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With SARS-CoV-2 Infection
Sponsor: Evelo Biosciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient study defined patient population
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-26
Primary completion date: 2021-05-16
Completion date: 2021-05-19
Plan to share individual participant data: NO
Clinical trial NCT04995978: Insulin Resistance and Androgen Deprivation Therapy
Official title: Insulin Resistance in Men With Prostate Cancer on Androgen Deprivation Therapy
Sponsor: St. Louis University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants were recruited and the study was deemed not feasible
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-01
Primary completion date: 2023-01-18
Completion date: 2023-01-18
Plan to share individual participant data: NO
Clinical trial NCT04606563: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
Official title: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
Acronym: ARBs CORONA II
Sponsor: University of British Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: DSMC recommendation due to futility
Enrollment: 341.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-09
Primary completion date: 2022-04-22
Completion date: 2022-04-22
Plan to share individual participant data: NO
Clinical trial NCT02462421: Pharmacogenetics of SGLT2 Inhibitors
Official title: Pharmacogenetics of Sodium-dependent Glucose Transporter-2 (SGLT2) Inhibitors
Acronym: SGLT2iPGx
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Did not meet recruitment targets.
Enrollment: 30.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-06-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Limitations and caveats: Small sample size: We had hoped to recruit more participants, but the need to collect two 24 hour urine samples turned out to be a major obstacle.~Small pilot study conducted in healthy volunteers rather than the target population for SGLT2 inhibitors.~Genetic studiy conducted in a Founder Population (Old Order Amish living in Lancaster County). Lancaster Amish chosen because of the availability of genotyping data and existence of infrastructure enabling genotype-directed call-back studies.
Plan to share individual participant data: NO
IPD sharing description: Individual participant data will not be shared in order to protect confidentiality of research subjects.
Clinical trial NCT04043845: ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Official title: A Phase 1 Study Targeting ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Business development reasons.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-03
Primary completion date: 2020-02-03
Completion date: 2020-02-03
Plan to share individual participant data: YES
IPD sharing description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD time frame: Data can be shared no earlier than 1 year following the date of publication
IPD access criteria: BCH - Contact the Technology \& Innovation Development Office at www.childrensinnovations.org or email TIDO@childrens.harvard.edu BIDMC - Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu BWH - Contact the Partners Innovations team at http://www.partners.org/innovation DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu MGH - Contact the Partners Innovations team at http://www.partners.org/innovation
Clinical trial NCT05101447: Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis
Official title: Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis
Acronym: PRUNE
Sponsor: Children's Hospital Medical Center, Cincinnati (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: funding not secured
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-07-31
Primary completion date: 2024-01-31
Completion date: 2024-07-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02456532: Safety and Efficacy of Chronic Hypnotic Use 2
Official title: Risks for Transition From Therapeutic Hypnotic Use to Abuse
Acronym: CIS2
Sponsor: Henry Ford Health System (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-08-05
Primary completion date: 2022-02-22
Completion date: 2022-02-22
Limitations and caveats: Difficulty reaching proposed enrollment target: 41 of projected 120 participants completed the study- in part due to COVID. Study is to be considered preliminary
Clinical trial NCT03827213: Exparel Interscalene vs Indwelling Catheter
Official title: Prospective Randomized Control Trial Evaluating Single Shot Exparel Versus Indwelling Interscalene Catheter for Total Shoulder Replacements- A Pilot Study
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Ran out of medication
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-22
Primary completion date: 2021-06-01
Completion date: 2021-06-01
Plan to share individual participant data: NO
Clinical trial NCT01903486: Assessing the Efficacy of Steroid Treatment of Achalasia
Official title: A Pilot Study Assessing the Efficacy of Steroids in the Treatment of Achalasia
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Unable to recruit participants.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-03-31
Primary completion date: 2020-12-28
Completion date: 2020-12-28
Clinical trial NCT04120194: Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
Official title: A Phase 3, Randomized, Observer-blinded, Active-controlled Trial to Evaluate Immunogenicity & Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With Matrix-M1™ Adjuvant Against Fluzone® Quadrivalent in Clinically Stable Adults ≥ 65 Years of Age
Sponsor: Novavax (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 2654.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-14
Primary completion date: 2020-10-29
Completion date: 2020-12-13
Baseline population: 2654 participants were randomized at a 1:1 ratio into 1 of 2 vaccine groups. Both groups were stratified by site, age (65 to \< 75 and ≥ 75 years), and history of prior year receipt of the 2018-2019 influenza vaccine. The Safety Population was analyzed as actually treated (ie, based on the actual dose received).
Plan to share individual participant data: NO
Clinical trial NCT02792413: Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
Official title: Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
Acronym: HDENO
Sponsor: University Hospital, Montpellier (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Modified study and new deposit in RECHMPL21_0451
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-19
Primary completion date: 2020-12-10
Completion date: 2020-12-10
Plan to share individual participant data: NO
Clinical trial NCT04583280: A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (<28 Days of Age), Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
Acronym: DAISY
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Janssen made the strategic decision to discontinue the DAISY study. This decision is not based on any safety concerns.
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-06
Primary completion date: 2022-03-18
Completion date: 2022-03-18
Limitations and caveats: As the study was terminated early, the Sponsor decided not to perform the complete analysis planned per protocol. Hence, data was collected and analyzed for safety, and selected PK and efficacy parameters only.
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT05234437: A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
Official title: A Phase IIb, Multicentre, Open Label Study to Evaluate the Effectiveness, Safety and Tolerability of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
Sponsor: QBiotics Group Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient Patient Recruitment Rates
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-03-09
Primary completion date: 2022-07-18
Completion date: 2022-07-18
Clinical trial NCT03384745: A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
Official title: A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Sponsor: Bond Avillion 2 Development LP (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 313.0 (ACTUAL)
Number of arms: 6.0
Start date: 2018-07-31
Primary completion date: 2019-06-20
Completion date: 2020-03-26
Clinical trial NCT02038634: Ultrasound-guided Injection for DeQuervain's
Official title: Ultrasound-guided Injection for DeQuervain's
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: not enough patient data
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-08-05
Primary completion date: 2021-03-15
Completion date: 2021-03-15
Limitations and caveats: Early termination due to lack of subject participation; statistical analysis not done due to small numbers. Outcome Measure # 2 was originally posted but was deleted as it was not included as part of the study design. No data was collected for that proposed outcome.
Plan to share individual participant data: NO
IPD sharing description: We have no plan to share the data we have collected with any other researchers.
Clinical trial NCT03248479: Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Official title: A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This study has been discontinued due to futility based on the results of a planned analysis of the ENHANCE trial.
Enrollment: 258.0 (ACTUAL)
Number of arms: 8.0
Start date: 2017-09-08
Primary completion date: 2023-09-05
Completion date: 2023-09-05
Plan to share individual participant data: NO
Clinical trial NCT03602898: Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Official title: A Randomized Phase II Study to Compare ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Insufficient funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-06-01
Primary completion date: 2023-09-17
Completion date: 2023-09-17
Plan to share individual participant data: NO
Clinical trial NCT03922477: A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Official title: A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The Sponsor decided to discontinue the development of atezolizumab in combination with magrolimab in the AML indication.
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-08
Primary completion date: 2020-11-03
Completion date: 2020-11-03
Plan to share individual participant data: NO
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT02097121: OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
Official title: BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-05-23
Primary completion date: 2022-02-10
Completion date: 2022-02-10
Baseline population: The BOTOX-treated population (all participants enrolled into the study who received at least 1 BOTOX treatment) according to the dose received in the first treatment cycle.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT03093454: Effects of Lavender Oil on Postoperative Pain, Sleep Quality and Mood
Official title: Effects of Lavender Oil on Postoperative Pain, Sleep Quality and Mood
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 58.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-27
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Baseline population: Participants who completed the study.
Plan to share individual participant data: NO
Clinical trial NCT03111238: The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
Official title: The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Rest Pain in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 4 and Diabetes Mellitus (DM): a Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial
Sponsor: Ixaka Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Stopped due to inactivity
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-05
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05323136: Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics
Official title: A Phase 1, Open-Label, Sequential, Adaptive, Single Dose Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of MT1002 for Injection
Sponsor: Shaanxi Micot Technology Limited Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic decision
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-15
Primary completion date: 2022-06-29
Completion date: 2022-06-29
Plan to share individual participant data: NO
Clinical trial NCT03297359: WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism
Official title: A Multicentre Prospective Cohort Study Assessing the Use of Weight-Adjusted Low-Molecular-Weight-Heparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism
Acronym: WAVe
Sponsor: Ottawa Hospital Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low recruitment
Enrollment: 92.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-21
Primary completion date: 2023-11-30
Completion date: 2023-11-30
Clinical trial NCT03509298: Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer
Official title: Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Pancreatic Cancer
Sponsor: Fuda Cancer Hospital, Guangzhou (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-04-12
Primary completion date: 2020-05-20
Completion date: 2020-07-12
Clinical trial NCT05117008: Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Official title: A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) After BCMA-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Acronym: EMBRACE
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low enrollment.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-07-19
Primary completion date: 2024-01-15
Completion date: 2024-01-15
Plan to share individual participant data: NO